The Prostatype® Test System combines gene expression information with the currently used clinical parameters (PSA, Gleason Score, Tumor Stage, and age). Based on a unique database containing authentic information from 600 historic prostate cancer patients, the Prostatype® Test System provides decision support for patients and doctors when making a treatment decision. This reduces the risk of over- or undertreatment and can postpone repeated biopsies.

Results
Based on the genetic profile and clinical data of the patient, the software identifies the three most similar reference patients from an authentic historic database. The treatment, survival time and cause of death of the reference patients is displayed and serve as a decision support when choosing the optimal treatment for the patient.
Example Report

For Patients
Prostate Cancer
Prostate cancer develops in the prostate gland. Unlike most other types of cancer, prostate cancer is slow growing in the majority of cases and only 10-15% of prostate tumors are rapidly progressing.1 Therefore, for most men diagnosed with prostate cancer the tumor does not pose a threat to the patient’s life. Usually, prostate cancer patients do not have any specific symptoms from an early stage prostate cancer. However, at later stages pain or difficulties urinating as well as problems during sexual intercourse are often experienced.
Prostatype® Test System

The Optimal Treatment
Less than 25 % of patients die from their prostate cancer. Nevertheless, up to 90 % receive radical treatment such as prostatectomy or radiation, although conservative strategies such as active surveillance would often be sufficient.

For Clinicians
Benefits
In current clinical practice, risk scoring systems such as D’Amico are commonly used when making a treatment decision for prostate cancer patients. However, selecting the treatment based on parameters such as Gleason Score is heavily dependent on visual assessment and human interpretation and is often challenging, particularly for patients in the intermediate risk zone.

Advantages
The test can be run at any molecular pathological laboratory providing short turnover times and full control.

The Prostatype® Test System – a new gene test for prostate cancer patients

patient_doctor

Decision Support

for Treatment

qualityoflife2

Maintaining

Quality of Life

prostatypetestkit

Objective

Second Opinion

over_undertreatment

Avoid

Over- or Undertreatment

 

The Test System

Results

Based on the genetic profile and clinical data of the patient, the Prostatype® Test System searches the three ...

For Patients

Prostate Cancer

Prostate cancer develops in the prostate gland. Unlike most other types of cancer, prostate cancer is slow ...

The Optimal Treatment

Prostate cancer at an early stage does not usually cause symptoms and is more commonly found by detection ...

For Clinicians

Benefits

A list of benefits the pathologist, the urologist as well as the patient receive by using the Prostatype® Test System.

Advantages

The Prostatype® Test System is provided in a kit-based format: The test can be run at any molecular ...

News

Urologidagarna in Jönköping

Chundsell Medicals presented the Prostatype® Test System at the Swedish National Urology Meeting in Jönköping ...

Award for Zhuochun Peng

Zhuochun Peng was awarded by the Chinese Government for the years’ best PhD thesis. Her outstanding research work ...

Read More